Click here to get full coverage on Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street - Yahoo Finance

Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street  Yahoo Finance

Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street - Yahoo Finance

Click here to get full coverage on CRBU Forecast, Price Target & Analyst Ratings | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill

CRBU Forecast, Price Target & Analyst Ratings | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU)  ChartMill

CRBU Forecast, Price Target & Analyst Ratings | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill

Click here to get full coverage on Caribou Biosciences (NASDAQ: CRBU) schedules virtual annual meeting June 17, 2026 - Stock Titan

Caribou Biosciences (NASDAQ: CRBU) schedules virtual annual meeting June 17, 2026  Stock Titan

Caribou Biosciences (NASDAQ: CRBU) schedules virtual annual meeting June 17, 2026 - Stock Titan

Click here to get full coverage on Caribou rises on FDA RMAT designation (CRBU:NASDAQ) - Seeking Alpha

Caribou rises on FDA RMAT designation (CRBU:NASDAQ)  Seeking Alpha

Caribou rises on FDA RMAT designation (CRBU:NASDAQ) - Seeking Alpha

Click here to get full coverage on $CRBU stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$CRBU stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$CRBU stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on CRBU: Pivotal trial planning advances for vispa-cel, with global commercialization and funding strategies outlined - TradingView — Track All Markets

CRBU: Pivotal trial planning advances for vispa-cel, with global commercialization and funding strategies outlined  TradingView — Track All Markets

CRBU: Pivotal trial planning advances for vispa-cel, with global commercialization and funding strategies outlined - TradingView — Track All Markets

Click here to get full coverage on AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™  Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

Click here to get full coverage on CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill

CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU)  ChartMill

CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill

Click here to get full coverage on Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates  Yahoo Finance

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on CRBU SEC Filings - Caribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

CRBU SEC Filings - Caribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms  Stock Titan

CRBU SEC Filings - Caribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Click here to get full coverage on Insider Sale: Chief Technology Officer of $CRBU Sells 3,147 Shares - Quiver Quantitative

Insider Sale: Chief Technology Officer of $CRBU Sells 3,147 Shares  Quiver Quantitative

Insider Sale: Chief Technology Officer of $CRBU Sells 3,147 Shares - Quiver Quantitative

Click here to get full coverage on Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why - Yahoo Finance

Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why  Yahoo Finance

Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why - Yahoo Finance

Click here to get full coverage on FDA grants RMAT designation to Caribou (CRBU) CAR-T CB-011 in multiple myeloma - Stock Titan

FDA grants RMAT designation to Caribou (CRBU) CAR-T CB-011 in multiple myeloma  Stock Titan

FDA grants RMAT designation to Caribou (CRBU) CAR-T CB-011 in multiple myeloma - Stock Titan

Click here to get full coverage on Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on FDA gives advanced therapy status to Caribou's myeloma CAR-T - Stock Titan

FDA gives advanced therapy status to Caribou's myeloma CAR-T  Stock Titan

FDA gives advanced therapy status to Caribou's myeloma CAR-T - Stock Titan

Click here to get full coverage on Caribou Biosciences (CRBU) Is Down 7.8% After Positive Phase 1 CAR-T Data and Phase 3 Trial Plans – Has The Bull Case Changed? - Yahoo Finance

Caribou Biosciences (CRBU) Is Down 7.8% After Positive Phase 1 CAR-T Data and Phase 3 Trial Plans – Has The Bull Case Changed?  Yahoo Finance

Caribou Biosciences (CRBU) Is Down 7.8% After Positive Phase 1 CAR-T Data and Phase 3 Trial Plans – Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Off-the-shelf CAR-T data in lymphoma and myeloma head to 2026 Tandem - Stock Titan

Off-the-shelf CAR-T data in lymphoma and myeloma head to 2026 Tandem  Stock Titan

Off-the-shelf CAR-T data in lymphoma and myeloma head to 2026 Tandem - Stock Titan

Click here to get full coverage on Assessing Caribou Biosciences (CRBU) Valuation After Early CB-011 CAR-T Data and Pipeline Progress - Yahoo Finance

Assessing Caribou Biosciences (CRBU) Valuation After Early CB-011 CAR-T Data and Pipeline Progress  Yahoo Finance

Assessing Caribou Biosciences (CRBU) Valuation After Early CB-011 CAR-T Data and Pipeline Progress - Yahoo Finance

Click here to get full coverage on Caribou Bio (NASDAQ: CRBU) to host Nov. 3 webcast on first CB-011 data, vispa-cel update - Stock Titan

Caribou Bio (NASDAQ: CRBU) to host Nov. 3 webcast on first CB-011 data, vispa-cel update  Stock Titan

Caribou Bio (NASDAQ: CRBU) to host Nov. 3 webcast on first CB-011 data, vispa-cel update - Stock Titan

Click here to get full coverage on CRBU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

CRBU Financials: Income Statement, Balance Sheet & Cash Flow  Stock Titan

CRBU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Click here to get full coverage on Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned - Stock Titan

Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned  Stock Titan

Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned - Stock Titan

Click here to get full coverage on H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9 - Moomoo

H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9  Moomoo

H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9 - Moomoo

Click here to get full coverage on Caribou (NASDAQ: CRBU): 51% 12-mo PFS with vispa-cel, on par with autologous CAR-T - Stock Titan

Caribou (NASDAQ: CRBU): 51% 12-mo PFS with vispa-cel, on par with autologous CAR-T  Stock Titan

Caribou (NASDAQ: CRBU): 51% 12-mo PFS with vispa-cel, on par with autologous CAR-T - Stock Titan

Click here to get full coverage on CRBU Stock: HC Wainwright & Co. Boosts Price Target to $9.00 | C - GuruFocus

CRBU Stock: HC Wainwright & Co. Boosts Price Target to $9.00 | C  GuruFocus

CRBU Stock: HC Wainwright & Co. Boosts Price Target to $9.00 | C - GuruFocus

Click here to get full coverage on Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value - Seeking Alpha

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value  Seeking Alpha

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value - Seeking Alpha

Click here to get full coverage on Caribou Biosciences (CRBU) CTO sells 6,228 shares in open-market trade - Stock Titan

Caribou Biosciences (CRBU) CTO sells 6,228 shares in open-market trade  Stock Titan

Caribou Biosciences (CRBU) CTO sells 6,228 shares in open-market trade - Stock Titan

Click here to get full coverage on Caribou Biosciences CLO sold $13,598 in CRBU stock - Investing.com

Caribou Biosciences CLO sold $13,598 in CRBU stock  Investing.com

Caribou Biosciences CLO sold $13,598 in CRBU stock - Investing.com

Click here to get full coverage on CRBU: Citigroup Analyst Raises Price Target for Caribou Bioscien - GuruFocus

CRBU: Citigroup Analyst Raises Price Target for Caribou Bioscien  GuruFocus

CRBU: Citigroup Analyst Raises Price Target for Caribou Bioscien - GuruFocus

Click here to get full coverage on CRBU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

CRBU Financials: Revenue Breakdown, Margins & Competitor Comparison  Intellectia AI

CRBU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Click here to get full coverage on Would You Still Hold Caribou Biosciences Stock If It Fell Another 30%? - Trefis

Would You Still Hold Caribou Biosciences Stock If It Fell Another 30%?  Trefis

Would You Still Hold Caribou Biosciences Stock If It Fell Another 30%? - Trefis

Click here to get full coverage on Caribou Biosciences (NASDAQ: CRBU) to participate in Truist Nov. 6, Evercore Dec. 2 - Stock Titan

Caribou Biosciences (NASDAQ: CRBU) to participate in Truist Nov. 6, Evercore Dec. 2  Stock Titan

Caribou Biosciences (NASDAQ: CRBU) to participate in Truist Nov. 6, Evercore Dec. 2 - Stock Titan

Click here to get full coverage on Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy - Seeking Alpha

Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy  Seeking Alpha

Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy - Seeking Alpha

Click here to get full coverage on Caribou Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview - TradingView — Track All Markets

Caribou Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview  TradingView — Track All Markets

Caribou Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview - TradingView — Track All Markets

Click here to get full coverage on Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know  Yahoo Finance

Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Click here to get full coverage on Caribou Biosciences: Key Data Updates Coming, Concerned About Volatility (NASDAQ:CRBU) - Seeking Alpha

Caribou Biosciences: Key Data Updates Coming, Concerned About Volatility (NASDAQ:CRBU)  Seeking Alpha

Caribou Biosciences: Key Data Updates Coming, Concerned About Volatility (NASDAQ:CRBU) - Seeking Alpha

Click here to get full coverage on Caribou Biosciences (CRBU): Revisiting Valuation Following Promising Phase 1 Clinical Trial Results - simplywall.st

Caribou Biosciences (CRBU): Revisiting Valuation Following Promising Phase 1 Clinical Trial Results  simplywall.st

Caribou Biosciences (CRBU): Revisiting Valuation Following Promising Phase 1 Clinical Trial Results - simplywall.st

Click here to get full coverage on Clear Street initiates coverage on Caribou Biosciences stock with Buy rating - Investing.com

Clear Street initiates coverage on Caribou Biosciences stock with Buy rating  Investing.com

Clear Street initiates coverage on Caribou Biosciences stock with Buy rating - Investing.com

Click here to get full coverage on Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Raises Target Price to $8 - 富途牛牛

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Raises Target Price to $8  富途牛牛

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Raises Target Price to $8 - 富途牛牛

Click here to get full coverage on Truist reiterates Buy on Caribou Biosciences stock, $7 target - Investing.com

Truist reiterates Buy on Caribou Biosciences stock, $7 target  Investing.com

Truist reiterates Buy on Caribou Biosciences stock, $7 target - Investing.com

Click here to get full coverage on Insights into Caribou Biosciences Q4 Earnings - Benzinga

Insights into Caribou Biosciences Q4 Earnings  Benzinga

Insights into Caribou Biosciences Q4 Earnings - Benzinga

Click here to get full coverage on Caribou Biosciences Announces The FDA Granted Regenerative Medicine Advanced Therapy (Rmat) Designation To Cb-011 - TradingView — Track All Markets

Caribou Biosciences Announces The FDA Granted Regenerative Medicine Advanced Therapy (Rmat) Designation To Cb-011  TradingView — Track All Markets

Caribou Biosciences Announces The FDA Granted Regenerative Medicine Advanced Therapy (Rmat) Designation To Cb-011 - TradingView — Track All Markets

Click here to get full coverage on BRIEF-Caribou Biosciences Q4 Licensing And Collaboration Revenue USD 3.941 Million - TradingView — Track All Markets

BRIEF-Caribou Biosciences Q4 Licensing And Collaboration Revenue USD 3.941 Million  TradingView — Track All Markets

BRIEF-Caribou Biosciences Q4 Licensing And Collaboration Revenue USD 3.941 Million - TradingView — Track All Markets

Click here to get full coverage on Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - Investing News Network

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma  Investing News Network

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - Investing News Network

Click here to get full coverage on CRBU PE Ratio & Valuation, Is CRBU Overvalued - Intellectia AI

CRBU PE Ratio & Valuation, Is CRBU Overvalued  Intellectia AI

CRBU PE Ratio & Valuation, Is CRBU Overvalued - Intellectia AI

Click here to get full coverage on Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Oncology Institute (TOI) - The Globe and Mail

Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Oncology Institute (TOI)  The Globe and Mail

Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Oncology Institute (TOI) - The Globe and Mail

Click here to get full coverage on Caribou Biosciences to Participate in Upcoming Investor Conferences - Investing News Network

Caribou Biosciences to Participate in Upcoming Investor Conferences  Investing News Network

Caribou Biosciences to Participate in Upcoming Investor Conferences - Investing News Network

Click here to get full coverage on Khan, Caribou Biosciences CBO, sells $13598 in stock - Investing.com

Khan, Caribou Biosciences CBO, sells $13598 in stock  Investing.com

Khan, Caribou Biosciences CBO, sells $13598 in stock - Investing.com

Click here to get full coverage on Caribou Biosciences Gains RMAT Status for CB-011 Therapy - TipRanks

Caribou Biosciences Gains RMAT Status for CB-011 Therapy  TipRanks

Caribou Biosciences Gains RMAT Status for CB-011 Therapy - TipRanks

Click here to get full coverage on Caribou Biosciences Is Exploding: Is CRBU the Next CRISPR Game-Changer or Just Hype? - AD HOC NEWS

Caribou Biosciences Is Exploding: Is CRBU the Next CRISPR Game-Changer or Just Hype?  AD HOC NEWS

Caribou Biosciences Is Exploding: Is CRBU the Next CRISPR Game-Changer or Just Hype? - AD HOC NEWS

Click here to get full coverage on Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? - Benzinga

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today?  Benzinga

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? - Benzinga

Click here to get full coverage on BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Cuts Target Price to $6 - 富途牛牛

BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Cuts Target Price to $6  富途牛牛

BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Cuts Target Price to $6 - 富途牛牛

Click here to get full coverage on Caribou Biosciences CTO Kelly sells $6.1k in shares - Investing.com

Caribou Biosciences CTO Kelly sells $6.1k in shares  Investing.com

Caribou Biosciences CTO Kelly sells $6.1k in shares - Investing.com

Click here to get full coverage on Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?  Yahoo Finance

Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Click here to get full coverage on Genomics Stocks That Deserve a Place in Your Portfolio in 2026 - Zacks Investment Research

Genomics Stocks That Deserve a Place in Your Portfolio in 2026  Zacks Investment Research

Genomics Stocks That Deserve a Place in Your Portfolio in 2026 - Zacks Investment Research

Click here to get full coverage on Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - Stocktwits

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments  Stocktwits

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - Stocktwits

Click here to get full coverage on $CRBU stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

$CRBU stock is up 15% today. Here's what we see in our data.  Quiver Quantitative

$CRBU stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN

Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results  MSN

Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN

Click here to get full coverage on CRBU | Caribou Biosciences, Inc. Common Analyst Forecasts - Quiver Quantitative

CRBU | Caribou Biosciences, Inc. Common Analyst Forecasts  Quiver Quantitative

CRBU | Caribou Biosciences, Inc. Common Analyst Forecasts - Quiver Quantitative

Click here to get full coverage on Khan, Caribou Biosciences CBO, sells $13598 in stock By Investing.com - Investing.com India

Khan, Caribou Biosciences CBO, sells $13598 in stock By Investing.com  Investing.com India

Khan, Caribou Biosciences CBO, sells $13598 in stock By Investing.com - Investing.com India

Click here to get full coverage on Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock? - Yahoo Finance

Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock?  Yahoo Finance

Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock? - Yahoo Finance

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance

Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In?  Yahoo Finance

Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance

Click here to get full coverage on The Truth About Caribou Biosciences: Is This CRISPR Stock the Next Big Mutation or Just Hype? - AD HOC NEWS

The Truth About Caribou Biosciences: Is This CRISPR Stock the Next Big Mutation or Just Hype?  AD HOC NEWS

The Truth About Caribou Biosciences: Is This CRISPR Stock the Next Big Mutation or Just Hype? - AD HOC NEWS

Click here to get full coverage on Caribou Biosciences: Gene?Editing Hopeful Caught Between Trial Hype and Small?Cap Volatility - AD HOC NEWS

Caribou Biosciences: Gene?Editing Hopeful Caught Between Trial Hype and Small?Cap Volatility  AD HOC NEWS

Caribou Biosciences: Gene?Editing Hopeful Caught Between Trial Hype and Small?Cap Volatility - AD HOC NEWS

Click here to get full coverage on With 60% ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) boasts of strong institutional backing - Yahoo Finance

With 60% ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) boasts of strong institutional backing  Yahoo Finance

With 60% ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) boasts of strong institutional backing - Yahoo Finance

Click here to get full coverage on Exclusive: Caribou's CEO Reveals CRISPR Innovation Strategy at Two Elite Investor Events - Stock Titan

Exclusive: Caribou's CEO Reveals CRISPR Innovation Strategy at Two Elite Investor Events  Stock Titan

Exclusive: Caribou's CEO Reveals CRISPR Innovation Strategy at Two Elite Investor Events - Stock Titan

Click here to get full coverage on Caribou Biosciences extends cash runway, focuses on oncology - Investing.com

Caribou Biosciences extends cash runway, focuses on oncology  Investing.com

CRBU

Price Chart

Key Statistics

Technicals

About CRBU

Latest News

Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street - Yahoo Finance

CRBU Forecast, Price Target & Analyst Ratings | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill

Caribou Biosciences (NASDAQ: CRBU) schedules virtual annual meeting June 17, 2026 - Stock Titan

Advanced Charts

Top Gainers

Top Losers